AASLD 2012

infohep news

• Hepatitis B

  Adding pegylated interferon to entecavir improves hepatitis B treatment response

  Liz Highleyman / 13 December 2012

  Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a presentation at The ...

• Treatment issues

  Adherence to hepatitis C treatment: unravelling the complexities

  Rob Camp / 13 December 2012

  Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ...

• Therapies

  Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients?

  Liz Highleyman / 12 December 2012

  An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot ...

• Treatment for previous non-responders & relapsers

  Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

  Liz Highleyman / 05 December 2012

  Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ...

• Hepatocellular carcinoma (HCC)

  Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising

  Liz Highleyman / 05 December 2012

  The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ...

• Therapies

  Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon

  Liz Highleyman / 03 December 2012

  An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C patients, according to findings from ...

• Hepatitis B

  Nucleoside analogues reduce hepatitis B liver cancer risk

  Liz Highleyman / 29 November 2012

  Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ...

• Treatment issues

  Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis

  Liz Highleyman / 23 November 2012

  The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved three-times-daily schedule, with similar safety ...

• Treatment issues

  Which patients should be prioritised for new hepatitis C treatments?

  Rob Camp / 23 November 2012

  Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ...

• Deciding when and how to treat HCV

  Low viral load in hepatitis C treatment: Is a third drug necessary?

  Rob Camp / 23 November 2012

  When resources for hepatitis C treatment with new directly acting antivirals are limited, findings from the United States suggest that previously untreated people with low viral loads may stand a good chance ...